MONTREAL, February 29, 2024 – Two widely prescribed classes of Type 2 diabetes medications-incretin-based therapies-are linked to a considerably lower risk of developing dementia, according to a sweeping new study from McGill University. Could managing blood sugar be a surprisingly effective way to protect your brain?
The research, analyzing data from over 450,000 patients, adds to a growing body of evidence suggesting these medications offer benefits beyond glucose control.
- A large-scale study links incretin-based d
Q: Can diabetes medications really help prevent dementia? A: This study suggests that certain diabetes medications, specifically incretin-based therapies like Ozempic and DPP-4 inhibitors, may reduce the risk of dementia, offering a potential new avenue for cognitive protection.
Type 2 diabetes increases the risk of dementia by approximately 60 percent, yet effective preventative strategies have been limited. With the number of Canadians living with dementia projected to reach one million by 2030, finding solutions is critical.
Stronger Protection with Consistent Use
The McGill team followed patients age 50 and older for roughly three years, comparing those newly prescribed incretin-based therapies to those starting sulfonylureas, a different class of diabetes medication. The results revealed a compelling trend.
DPP-4 inhibitors were associated with a 23-percent reduction in dementia risk compared to sulfonylureas, which are not known to provide cognitive benefits. Importantly, the longer patients used DPP-4 inhibitors and the higher the dosage, the more pronounced the protective effect became. GLP-1 receptor agonists, including medications like Ozempic, showed a similar, though less definitive, pattern due to a smaller patient sample.
“While GLP-1 drugs have garnered significant attention,our findings indicate that DPP-4 inhibitors also warrant further inquiry,” said Dr. Christel Renoux, associate professor in McGill’s Department of Neurology and Neurosurgery and senior investigator at the Lady Davis Institute.
A More Rigorous Approach to Research
Previous studies hinting at the cognitive benefits of incretin-based therapies often lacked comprehensive patient health data, particularly regarding the severity of diabetes-a major risk factor for dementia. This new research leveraged detailed clinical data from the U.K.’s Clinical Practice Research Datalink, allowing researchers to control for these and other confounding factors, resulting in a more reliable comparison.
“These results provide robust evidence supporting a suspicion scientists have held for some time,” Renoux explained. “these drugs may offer advantages extending far beyond blood-sugar regulation, benefits we are only beginning to understand.”
Renoux emphasized the need for continued long-term studies to confirm these findings, including research focused on individuals currently using GLP-1 drugs for weight management.
